- First Online:
- 253 Downloads
Levofloxacin (Levaquin®) is a fluoroquinolone antibacterial that is the L-isomer of ofloxacin. A high-dose (750 mg) short-course (5 days) of once-daily levofloxacin is approved for use in the US in the treatment of community-acquired pneumonia (CAP), acute bacterial sinusitis (ABS), complicated urinary tract infections (UTI) and acute pyelonephritis (AP).
The broad spectrum antibacterial profile of levofloxacin means that monotherapy is often a possibility in patients with CAP at times when other agents may require combination therapy, although levofloxacin can be used in combination therapy when necessary. The high-dose, short-course levofloxacin regimen maximizes its concentration-dependent bactericidal activity and may reduce the potential for resistance to emerge. In addition, this regimen lends itself to better compliance because of the shorter duration of treatment and the convenient once-daily administration schedule.
Oral levofloxacin is rapidly absorbed and is bioequivalent to the intravenous formulation; importantly, patients can transition between the formulations, which results in more options in regards to the treatment regimen and the potential for patients with varying degrees of illness to be treated. Levofloxacin has good tissue penetration and an adequate concentration can be maintained in the urinary tract to treat uropathogens.
Levofloxacin is generally well tolerated and has good efficacy in the treatment of patients with CAP, ABS, complicated UTI and AP. The efficacy and tolerability of levofloxacin 500 mg once daily for 10 days in patients with CAP, ABS and UTIs is well established, and the high-dose, short-course levofloxacin regimen has been shown to be noninferior to the 10-day regimen in CAP and ABS, and to have a similar tolerability profile. Similarly, the high-dose, short-course levofloxacin regimen is noninferior to ciprofloxacin in patients with complicated UTI or AP. Thus, levofloxacin is a valuable antimicrobial agent that has activity against a wide range of bacterial pathogens; however, its use should be considered carefully so that the potential for resistance selection can be minimized and its usefulness in severe infections and against a range of penicillin- and macrolide-resistant pathogens can be maintained.
Levofloxacin is the synthetic L-isomer of the racemic quinolone ofloxacin. It interferes with critical processes in the bacterial cell, such as DNA replication, transcription, repair and recombination, by inhibiting type II topoisomerases. Levofloxacin is active against a broad range of Gram-positive, Gram-negative and atypical bacteria that may be causative pathogens in community-acquired and nosocomial infections.
In general, levofloxacin shows good in vitro activity against clinically-relevant Gram-positive, -negative and atypical organisms. Levofloxacin is active against the Gram-positive penicillin-susceptible and -resistant strains of Streptococcus pneumoniae, the Gram-negative species Enterobacter cloacae and Proteus mirabilis, and the atypical organisms Chlamydophila pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae, with minimum concentrations required to inhibit the growth of 90% of strains (MIC90) of ≤2 mg/L. Levofloxacin is highly active against the Gram-negative species Haemophilus influenzae, H. parainfluenzae and Moraxella catarrhalis (MIC90 of ≤0.06 mg/L), including β-lactamase positive strains of H. influenzae and M. catarrhalis. The activity of levofloxacin against Gram-positive meticillin/oxacillin-susceptible Staphylococcus aureus is slightly reduced, with the MIC90 (≤4 mg/L) in the susceptible to intermediate range, and the activity of levofloxacin against the Gram-negative Escherichia coli (MIC90 ≤0.06 to >8 mg/L) and Pseudomonas aeruginosa (MIC90 0.5–64 mg/L) is variable.
Rates of S. pneumoniae resistance to levofloxacin have remained ≤1% in surveillance programmes undertaken in the US, Canada and worldwide; in penicillin-resistant isolates of S. pneumoniae, the rate of resistance to levofloxacin was ≤2.7%. Recent data suggest that the rate of levofloxacin resistance in S. pneumoniae in the US has decreased between 2004 and 2006. Levofloxacin resistance has not been identified in H. influenzae or M. catarrhalis in surveillance studies conducted up to 2005, but it has been identified in E. coli, P. aeruginosa and S. aureus.
As the activity of levofloxacin is concentration dependent, the most common predictor of microbiological and clinical efficacy is the area under the plasma concentration-time curve (AUC): MIC ratio. A ratio of >30 was used in some studies to predict in vivo activity, particularly against S. pneumoniae, but a higher ratio (>100) is suggested as being predictive of a bactericidal effect and thus reducing the potential of first-step mutations occurring. In simulated pharmacodynamic analyses of levofloxacin 750 mg, the probability of an AUC: MIC target of ≥30 being attained in the plasma was ≥97%.
Following oral administration, levofloxacin is rapidly absorbed and maximum plasma concentrations are attained in 1–2 hours. The absolute bioavailability of levofloxacin is ≈99% and the oral solution or tablet formulations and intravenous formulation are bioequivalent. Plasma protein binding is low (≤38%). Levofloxacin is distributed throughout the body and the concentration in other tissues (e.g. epithelial lining fluid, alveolar cells or macrophages, paranasal sinuses mucosa and urine) can exceed that in the plasma 2–4 hours after administration.
The pharmacokinetics of levofloxacin are not affected by age, gender, race, HIV status or the presence of a serious community-acquired bacterial infection. However, gastrointestinal absorption of the drug can be reduced by magnesium- or aluminium-containing antacids, metal cations, such as iron and vitamin preparations with zinc, as well as sucralfate. The concomitant use of levofloxacin with a range of other drugs has not resulted in any clinically significant effects in a small number of formal drug interaction studies. Clinically significant effects, such as symptomatic hyperglycaemia and hypoglycaemia, have been reported with levofloxacin, usually in patients with diabetes mellitus receiving concomitant hypoglycaemic agents/insulin. Postmarketing experience includes reports that levofloxacin enhances the effects of warfarin.
The efficacy of oral and/or intravenous levofloxacin 750 mg once daily for 5 days has been established in randomized, well designed trials in adults with CAP, ABS, complicated UTI or AP. Levofloxacin 750 mg once daily for 5 days was noninferior to levofloxacin 500 mg once daily for 10 days in the treatment of adults with CAP and ABS infections according to the primary endpoint of clinical response rate 7–14 days after the end of treatment. Clinical and microbiological response rates in the clinically evaluable population of patients with CAP were 92.4% versus 91.1% and 93.2% versus 92.4% in those receiving the 750 mg dosage regimen versus the 500 mg dosage regimen. In patients with ABS, the corresponding response rates were 91.4% versus 88.6% and 91.5% versus 89.4%, respectively.
Levofloxacin 750 mg once daily for 5 days was noninferior to ciprofloxacin 400 mg or 500 mg twice daily for 10 days in the treatment of adults with complicated UTI or AP infections according to the primary endpoint of microbiological response (eradication) rate on day 15–22 of the study. The microbiological response rate in levofloxacin or ciprofloxacin recipients (all patients with complicated UTI or AP) in the co-primary endpoint populations was 79.8% versus 79.8% (modified intent-to-treat population) and 86% versus 89.2% (microbiologically evaluable population). Clinical response rates in the corresponding groups were 81.1% versus 80.1% and 86.4% versus 88.4%, respectively.
Levofloxacin is generally well tolerated in patients with respiratory or UTIs. In a pooled analysis of patients with respiratory infections, the most commonly reported treatment-emergent adverse events included nausea, headache, diarrhoea, insomnia, constipation, abdominal pain, dizziness, dyspepsia and vomiting; the incidence of drug-related adverse events was not significantly different between those receiving the levofloxacin 750 mg or 500 mg regimen. No clinically important adverse events that occurred were deemed to be drug related. Discontinuation of therapy because of drug-related adverse events occurred in <2% of patients with respiratory infections. The most common treatment-emergent adverse events in patients with complicated UTI or AP were similar to those observed in patients with respiratory infections.
Unable to display preview. Download preview PDF.
- 1.Jones RN, Fritsche TR, Sader HS, et al. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Diagn Microbiol Infect Dis 2007 May; 58(1): 9–17PubMedCrossRefGoogle Scholar
- 6.Huband MD, Cohen MA, Zurack M, et al. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Antimicrob Agents Chemother 2007 Apr; 51(4): 1191–201PubMedCrossRefGoogle Scholar
- 10.Levaquin® (levofloxacin tablets, oral solution, injection): US prescribing information. Raritan (NJ): Ortho-McNeil Pharmaceutical, Inc., 2008 JanGoogle Scholar
- 12.Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard — seventh edition. Clinical and Laboratory Standards Institute Document M7-A7. Wayne (PA): Clinical and Laboratory Standards Institute, 2006 Jan: 26 (2)Google Scholar
- 13.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests. Approved standard — ninth edition. Clinical and Laboratory Standards Institute Document M2-A9. Wayne (PA): Clinical and Laboratory Standards Institute, 2006 Jan: 261Google Scholar
- 14.Huband MD, Brighty KE, Monohan R, et al. In vitro antibacterial activity of CE-156811, CP-919474, and CP-929898: novel hygromycin A analogs compared to levofloxacin and other antibacterial agents against 1220 recent clinical isolates [abstract no. F1-1963]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA), 230Google Scholar
- 16.Fritsche TR, Sader HS, Jones RN. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999–2004). Diagn Microbiol Infect Dis 2007 May; 58(1): 19–26PubMedCrossRefGoogle Scholar
- 20.Sahm DF, Weaver MK, Flamm RK, et al. Rates of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States: results from the TRUST 7 (2002–2003) surveillance study [abstract no. 201 plus poster]. 41st Annual Meeting of the Infectious Diseases Society of America; 2003 Oct 9–12; San Diego (CA)Google Scholar
- 25.Biedenbach DJ, Toleman MA, Walsh TR, et al. Characterization of fluoroquinolone-resistant β-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY antimicrobial surveillance program (1997–2004).Diagn Microbiol Infect Dis 2006 Jun; 55(2): 119–27PubMedGoogle Scholar
- 26.Bouchillon S, Hackel M, Johnson J, et al. The carbapenem PZ-601 (SMP-601) has potent in vitro Gram-positive, Gram-negative and anaerobic bacterial activity (poster F1-343). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)Google Scholar
- 27.Paterson DL, Adams J, Doi Y. In vitro activity of PZ-601 (SMP-601), a novel carbapenem, against extended-spectrum beta-lactamase producing organisms [poster no. F1-346]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)Google Scholar
- 28.Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000. Clin Infect Dis 2002 Mar 1; 34 Suppl. 1: S4–16PubMedCrossRefGoogle Scholar
- 29.Karlowsky JA, Thornsberry C, Critchley IA, et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000–2001 and 2001–2002 TRUST studies in the United States. Antimicrob Agents Chemother 2003 Jun; 47(6): 1790–7PubMedCrossRefGoogle Scholar
- 31.Soriano F, Granizo JJ, Coronel P, et al. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project. Int J Antimicrob Agents 2004 Mar; 23(3): 296–9Google Scholar
- 33.Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18 569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY antimicrobial surveillance program (1997–2001). Int J Antimicrob Agents 2003 Dec; 22(6): 551–6PubMedCrossRefGoogle Scholar
- 34.Pfaller MA, Sader HS, Fritsche TR, et al. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY antimicrobial surveillance program (1998–2004). Diagn Microbiol Infect Dis 2006 Sep; 56(1): 63–8PubMedCrossRefGoogle Scholar
- 38.Roblin PM, Reznik T, Kutlin A, et al. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 2003 Mar; 47(3): 1135–6PubMedCrossRefGoogle Scholar
- 51.LaPlante KL, Rybak MJ, Tsuji B, et al. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother 2007 Apr; 51(4): 1315–20PubMedCrossRefGoogle Scholar
- 53.Davies TA, Yee C, Morrow B, et al. Continued decline in levofloxacin-resistance among U.S. Streptococcus pneumoniae collected in TRUST 10 (2006) [abstract no. C2-210]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)Google Scholar
- 55.Frei CR, Burgess DS. Pharmacodynamic analysis of ceftriaxone, gatifloxacin, and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation. Pharma-cotherapy 2005 Sep; 25(9): 1161–7Google Scholar
- 56.Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother 2003 Oct; 37(10): 1478–88Google Scholar
- 57.Odenholt I, Cars O. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother 2006 Nov; 58(5): 960–5PubMedCrossRefGoogle Scholar
- 58.Noreddin AM, Hoban DJ, Zhanel GG. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int J Antimicrob Agents 2005 Aug; 26(2): 120–5PubMedCrossRefGoogle Scholar
- 59.Noreddin AM, Marras TK, Sanders K, et al. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents 2004 Nov; 24(5): 479–84PubMedCrossRefGoogle Scholar
- 62.Stein G, Schooley S, Nicolau D. Urinary bactericidal activity of levofloxacin (750 mg) against fluoroquinolone-resistant [abstract no. P1533]. Clin Microbiol Infect 2006 Apr 1; 12 (Suppl. 4)Google Scholar
- 75.Peterson J, Kaul S, Khashab M, et al. A double-blind, randomized comparison of levofloxacin 750mg once-daily for 5 days with ciprofloxacin 400/500mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 2008; 71: 17–22PubMedCrossRefGoogle Scholar
- 81.Peterson J, Khashab MM, Fisher AC, et al. Sustained early resolution of community-acquired pneumonia symptoms following treatment with high-dose, short-course levofloxacin [abstract no. 421 plus poster]. 44th Annual Meeting of the Infectious Diseases Society of America; 2006 Oct 12–16; Toronto (ON)Google Scholar
- 83.Wargo KA, Wargo NA, Eiland III EH. Maximizing pharmaco-dynamics with high-dose levofloxacin. Hosp Pharm 2005; 40(9): 777–87Google Scholar
- 91.Nickel JC. Management of urinary tract infections: historical perspective and current strategies: part 2. Modern management. J Urol 2005 Jan; 173(1): 27–32Google Scholar
- 93.Bhavnani SM, Ambrose PG, Craig WA, et al. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2006 Mar; 54(3): 231–6PubMedCrossRefGoogle Scholar
- 97.Yee YC, Evangelista AT, Obot-Tucker M, et al. Five-year surveillance (2003–2007) of anti-pneumococcal activity of oral agents recommended for the empirical treatment of community-acquired pneumonia (CAP) in adults [abstract no. C2-204]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)Google Scholar
- 100.Tobramycin (for injection, USP): US prescribing information. Schaumburg (IL): American Pharmaceutical Partners, Inc., 2003 OctGoogle Scholar
- 102.Biaxin® Filmtab® (clarithromycin tablets, USP), Biaxin® XL Filmtab® (clarithromycin extended-release tablets), Biaxin® Granules (clarithromycin for oral suspension, USP): US prescribing information. North Chicago (IL): Abbott Laboratories, 2005 JanGoogle Scholar
- 103.Abbott Laboratories. Erythrocin® stearate (erythromycin stearate tablets, USP): US patient information [online]. Available from URL: http://www.rxabbott.com/pdf/erythrocin.pdf [Accessed 2007 Nov 12]
- 104.Vantin® (cefpodoxime proxetil tablets and cefpodoxime proxetil for oral suspension): US prescribing information. New York (NY): Pharmacia & Upjohn Company, 2007 AprGoogle Scholar
- 105.Rocephin® (ceftriaxone sodium for injection): US prescribing information. Nutley (NJ): Roche Laboratories Inc., 2007 JanGoogle Scholar
- 106.Hospira I. Gentamicin sulfate (injection): US professional information [online]. Available from URL: http://www.drugs.com/pro/gentamicin-sulfate.html [Accessed 2007 Nov 12]
- 107.Hospira I. Amikacin (injection, USP): US professional information [online]. Available from URL: http://www.drugs.com/pro/amikacin.html [Accessed 2007 Nov 12]